C. Furberg

J. Danesh, R. Collins, A. Hofman, 2007, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Quality control procedures for the resting electrocardiogram in the Multiple Risk Factor Intervention Trial.

C. Furberg, R. Prineas, P. Rautaharju, 1986, Controlled clinical trials.

Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease

M. Pfeffer, C. Furberg, F. Sacks, 2005, Circulation.

Developing an optimal approach to global drug safety.

C. Furberg, R. Balkrishnan, 2001, Journal of internal medicine.

Developing an optimal approach to global drug safety

C. Furberg, R. Balkrishnan, 2001 .

Recruitment of Study Participants

D. DeMets, D. Reboussin, C. Granger, 2015 .

Republished: Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications

P. Enright, C. Furberg, Sonal Singh, 2014, Postgraduate Medical Journal.

I, RATIONALE AND DESIGN

B. Davis, J. Cutler, N. Borhani, 1991 .

Estrogen Replacement Therapy and Progression of Intimal-Medial Thickness in the Carotid Arteries of Postmenopausal Women

C. Furberg, W. Applegate, M. Espeland, 1995 .

Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study

C. Furberg, A. Newman, M. Criqui, 2016, Arteriosclerosis, thrombosis, and vascular biology.

Effect of Pravastatin on Cardiovascular Events in People With Chronic Kidney Disease

John Simes, Marcello Tonelli, Frank M. Sacks, 2004, Circulation.

Association Between Blood Pressure Level and the Risk of Myocardial Infarction, Stroke, and Total Mortality

T. Lumley, P. Savage, L. Kuller, 2001 .

Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study.

T. Lumley, P. Savage, L. Kuller, 2001, Archives of internal medicine.

Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency

B. Psaty, C. Furberg, T. Manolio, 2003, Circulation.

Creatinine levels and cardiovascular events in women with heart disease: do small changes matter?

E. Vittinghoff, C. Furberg, N. Wenger, 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Coronary Heart Disease in Patients With Low LDL-Cholesterol: Benefit of Pravastatin in Diabetics and Enhanced Role for HDL-Cholesterol and Triglycerides as Risk Factors

M. Pfeffer, A. Keech, E. Braunwald, 2002, Circulation.

Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

B. Davis, S. Oparil, W. Cushman, 2012, Hypertension.

The use of beta-adrenergic blocking drugs in patients with myocardial infarction.

C. Furberg, W. Friedewald, W. Frishman, 1984, Current problems in cardiology.

Call for worldwide withdrawal of tiotropium Respimat mist inhaler

P. Enright, C. Furberg, Sonal Singh, 2012, BMJ : British Medical Journal.

The causal exposure model of vascular disease

C. Furberg, P. Lawler, J. de Graaf, 2011, Clinical science.

Lipid-lowering trials: results and limitations.

C. Furberg, 1994, American heart journal.

Preventing atherosclerosis and its complications: Promising alternatives for the future: Introduction

C. Furberg, B. Pitt, 1994 .

Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older Adults The Cardiovascular Coronary Heart Disease

N. Powe, B. Psaty, C. Furberg, 2006 .

Are we biased in our approach to treating elderly patients with heart disease?

C. Furberg, S. Yusuf, 1991, The American journal of cardiology.

Contemplating ACTION—long-acting nifedipine in stable angina

B. Psaty, C. Furberg, B. Psaty, 2004, The Lancet.

Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.

B. Psaty, D. Siscovick, C. Furberg, 1997, JAMA.

Recent trials in hypertension: compelling science or commercial speech?

B. Psaty, C. Furberg, N. Weiss, 2006, JAMA.

Comparison of calcium channel blockers with other classes of drugs for hypertension

B. Psaty, C. Furberg, M. Pahor, 2006 .

Chlorthalidone vs Other Low-Dose Diuretics—Reply

T. Lumley, B. Psaty, C. Furberg, 2004 .

Doxazosin, an inferior antihypertensive agent?

C. Furberg, 2002, Journal of Human Hypertension.

Evidence-based medicine: worship of form and treatment of high blood pressure.

B. Psaty, C. Furberg, C. Rhoads, 2000, Journal of general internal medicine.

Hypertension and diabetes: current issues.

C. Furberg, 1999, American heart journal.

New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes.

B. Psaty, C. Furberg, M. Pahor, 1998, Journal of cardiovascular pharmacology.

JNC VI guidelines

B. Psaty, C. Furberg, 1998, The Lancet.

Primary Prevention of Cardiovascular Disease Endpoints Using β-Blockers-Reply

B. Psaty, C. Furberg, T. Koepsell, 1997 .

Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies.

T. Lumley, B. Psaty, C. Furberg, 2004, Journal of the American Medical Association (JAMA).

Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure

B. Psaty, C. Furberg, 2004, ACP journal club.

Improving cardiac outcomes after noncardiac surgery.

C. Furberg, J. Butterworth, 2003, Anesthesia and analgesia.

The pitfalls of inappropriate methods

K. Bailey, C. Furberg, S. Yusuf, 2005 .

Observed Benefits of Antihypertensive Drug Treatment Results of the Trials of Traditional Therapy Controlled Clinical Trials of Drug Treatment for Hypertension

J. Cutler, C. Furberg, A. Review, 2005 .

Calcium channel blockers in myocardial infarction: Authors' reply

C. Furberg, S. Yusuf, P. Held, 1990 .

10 – The Role of Beta Blockers in the Prevention of Sudden Cardiac Death in the Postinfarction Patient

C. Furberg, P. Frommer, 1986 .

Clinical Trials in Hypertension and Congestive Heart Failure

S. Yusuf, J. Cutler, C. Furberg, 1986 .

Should every survivor of a heart attack be given a beta-blocker?

C. Furberg, L. Friedman, J. Cutler, 1982, British medical journal.

Withdrawal of cerivastatin from the world market

Bertram Pitt, C. Furberg, B. Pitt, 2001, Current controlled trials in cardiovascular medicine.

The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions

C. Furberg, 2001, Current controlled trials in cardiovascular medicine.

Potential for altering the natural history of congestive heart failure: need for large clinical trials.

S. Yusuf, C. Furberg, T. Thom, 1985, The American journal of cardiology.

Effect of vasodilators on survival in chronic congestive heart failure.

C. Furberg, S. Yusuf, 1985, The American journal of cardiology.

Data Collection and Quality Control

D. DeMets, D. Reboussin, C. Granger, 2015 .

Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?

B. Psaty, C. Furberg, B. Psaty, 2003, Circulation.

Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-Up (HERS II)

E. Vittinghoff, J. Cauley, C. Furberg, 2002 .

Blood Pressure and Cardiovascular Disease

B. Psaty, C. Furberg, E. Soliman, 2010 .

Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review.

C. Furberg, J. Crouse, G. Tell, 1988, Stroke.

Balancing commercial and public interests

M. Sevick, C. Furberg, M. Hall, 2004, Current controlled trials in cardiovascular medicine.

Calcium channel blocker use and gastrointestinal tract bleeding among older adults

B. Psaty, C. Furberg, T. Koepsell, 2001 .

Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group.

C. Furberg, J. Corson, W. Riley, 1996, Stroke.

Effect of Cholesterol-Lowering Medications on Progression of Mild Atherosclerotic Lesions of the Carotid Arteries and on the Risk of Stroke

C. Furberg, H. Adams, R. Byington, 1995 .

Quality control in ultrasound studies on atherosclerosis

C. Furberg, R. Barnes, C. Furberg, 1994, Journal of internal medicine.

Isolated systolic hypertension and subclinical cardiovascular disease in the elderly. Initial findings from the Cardiovascular Health Study.

L H Kuller, P M Rautaharju, B M Psaty, 1992 .

Relative impact of lovastatin and estrogen replacement therapy on progression of intimal-medial thickness in the carotid arteries

C. Furberg, W. Applegate, M. Espeland, 1994 .

Predictors of carotid atherosclerosis progression

C. Furberg, W. Applegate, G. Evans, 1994 .

Calcium Antagonists and Cancer: Causation or Association?

C. Furberg, M. Pahor, 1998, Cardiovascular Drugs and Therapy.

Isradipine in Prediabetic Hypertensive Subjects

C. Furberg, M. Pahor, T. Craven, 1998, Diabetes Care.

Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events

C. Furberg, M. Pahor, T. Craven, 1997, The Lancet.

The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)

C. Furberg, W. Applegate, R. Byington, 1997, JAMA.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

C. Furberg, M. Bond, T. Craven, 1995, The American journal of cardiology.

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).

C. Furberg, B. Pitt, W. Riley, 1997, The American journal of cardiology.

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.

C. Furberg, W. Applegate, H. Adams, 1994, Circulation.

Low-dose metoprolol CR/XL and fluvastatin slowed progression of carotid atherosclerosis in asymptomatic patients with carotid plaque: Ramipril had a beneficial effect on the progression of atherosclerosis in patients at high risk for cardiovascular events

C. Furberg, G. Evans, 2001 .

Reversing risk in coronary disease

C. Furberg, R. Byington, 1995, The Lancet.

Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study.

C. Furberg, W. Applegate, M. Espeland, 1995, American journal of epidemiology.

Beta-adrenergic blockade for survivors of acute myocardial infarction.

C. Furberg, W. Friedewald, W. Frishman, 1984, The New England journal of medicine.

Use of beta-adrenergic blocking agents after myocardial infarction.

C. Furberg, W. Frishman, J. Ruggio, 1985, Postgraduate medicine.

Clinical Trials of Modification of Mortality During Acute Myocardial Infarction

C. Furberg, W. Friedewald, 1985 .

THERAPY AND PREVENTION

C. Furberg, C. M. Hawkins, E. Lichstein, 2005 .

Diuretic Agents Versus β‐Blockers Comparison of Effects on Mortality, Stroke, and Coronary Events

J. Cutler, C. Furberg, Curt D. Furberg, 1989, Hypertension.

Effect of antiarrhythmic drugs on mortality after myocardial infarction.

C. Furberg, 1983, The American journal of cardiology.

Fundamentals of Clinical Trials

D. DeMets, C. Furberg, L. Friedman, 1982 .

Author's response to reviews Title: Dealing with Heterogeneity of Treatment Effects: Is the Literature Up to the Challenge? A Systematic Review Authors:

J. Grimshaw, C. Furberg, D. Altman, 2009 .

Calcium supplements increase risk of myocardial infarction

C. Furberg, Sonal Singh, 2010, Evidence Based Medicine.

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Kahn et al.

T. Lumley, B. Psaty, C. Furberg, 2006, Diabetes care.

Corrections to the nifedipine meta-analysis.

B. Psaty, C. Furberg, 1996, Circulation.

Tiotropium and the risk of death in COPD.

C. Furberg, Sonal Singh, Y. Loke, 2014, The New England journal of medicine.

Hormone treatment--misconceptions and agreements.

E. Vittinghoff, C. Furberg, D. Herrington, 2002, European heart journal.

Plasma Renin Testing to Guide Antihypertensive Therapy

C. Furberg, A. Viera, 2014, Current Hypertension Reports.

Renin test-guided drug treatment of hypertension: the need for clinical trials.

C. Furberg, 2011, American Journal of Hypertension.

Renin-guided treatment of hypertension: time for action.

C. Furberg, 2010, American journal of hypertension.

Double‐blindness protects scientific validity

C. Furberg, E. Soliman, C. Furberg, 2008, Journal of thrombosis and haemostasis : JTH.

Surrogates, semantics, and sensible public policy.

C. Furberg, B. Sobel, 1997, Circulation.

Antiarrhythmics and VPD suppression.

C. Furberg, S. Yusuf, 1991, Circulation.

Current Controlled Trials in Cardiovascular Medicine

M. Sevick, C. Furberg, 2004 .

A new era in hypertension research: discussing the findings of ALLHAT

C. Furberg, 2001, Current controlled trials in cardiovascular medicine.

ALLHAT: Setting the Record Straight

B. Davis, Jackson T. Wright, P. Whelton, 2004, Annals of Internal Medicine.

Response to Letter Regarding Article, “Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)”

B. Davis, J. Cutler, M. Proschan, 2006 .

Treatment of dyslipidemia: room for improvement?

C. Furberg, J. Crouse, 2000, Arteriosclerosis, thrombosis, and vascular biology.

Charles J. Kahi, Deepak L. Bhatt, E. Antman, 2010, The American Journal of Gastroenterology.

Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side.

B. Psaty, C. Furberg, B. Psaty, 1995, Archives of internal medicine.

Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.

C. Furberg, H. Sinzinger, H. Kritz, 2003, Medical science monitor : international medical journal of experimental and clinical research.

Monitoring Committees: Why and How

D. DeMets, C. Furberg, L. Friedman, 2006 .

Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia.

C. Furberg, R. Byington, S. Goldstein, 1986, Journal of the American College of Cardiology.

Treatment of hypertensive patients with diabetes

B. Psaty, C. Furberg, M. Pahor, 1998, The Lancet.

Secondary prevention after myocardial infarction: a review of long-term trials.

D L DeMets, D. DeMets, C. Furberg, 1982, Progress in cardiovascular diseases.

Secondary prevention trials after acute myocardial infarction.

C. Furberg, 1987, The American journal of cardiology.

The Systolic Hypertension in the Elderly Program (SHEP): Rationale, Design, Recruitment, and Baseline Data

B. Davis, J. Cutler, N. Borhani, 1989 .

The Systolic Hypertension in the Elderly Program (SHEP): an intervention trial on isolated systolic hypertension. SHEP Cooperative Research Group.

B. Davis, J. Cutler, N. Borhani, 1989, Clinical and experimental hypertension. Part A, Theory and practice.

Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002.

I. Cockburn, C. Furberg, R. Stafford, 2004, JAMA.

Is the Use of Some Calcium Antagonists Linked to Cancer?

C. Furberg, M. Pahor, 1998, Drugs & aging.

Antihypertensive drugs decrease risk of Alzheimer disease Ginkgo Evaluation of Memory Study

K. Sink, L. Fried, S. DeKosky, 2022 .

The COX-2 inhibitors--an update.

C. Furberg, 2006, American heart journal.

Antihypertensive drug therapies and the risk of ischemic stroke.

B. Psaty, C. Furberg, S. Heckbert, 2001, Archives of internal medicine.

Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease".

C. Furberg, Sonal Singh, 2011, Archives of internal medicine.

Improved ECG models for estimation of left ventricular hypertrophy progression and regression incidence by redefinition of the criteria for a significant change in left ventricular hypertrophy status. The MRFIT Research Group. Multiple Risk Factor Intervention Trial.

C. Furberg, R. Prineas, J. Neaton, 1993, Journal of electrocardiology.

The beta-blocker heart attack trial.

C. Furberg, 1982, British journal of clinical pharmacology.

Adrenergic Beta-receptor Blockade and the Relationships between Physical Working Capacity, Heart Volume, and the Total Amount of Hemoglobin

C. Furberg, 1967 .

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

Sanjay Kaul, James Scheiman, Deepak L. Bhatt, 2008, Journal of the American College of Cardiology.

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

Barry J. Davis, M. Landray, R. Collins, 2022, The Lancet.

Risk of psychiatric side effects with varenicline

T. J. Moore, C. Furberg, T. Moore, 2009, BMJ : British Medical Journal.

Dyslipoproteinemia in North America: The Lipid Research Clinics Program Prevalence Study.

J. Hanley, S. Yusuf, K. Bailey, 1986, Circulation.

Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at high risk of symptomatic coronary heart disease.

C. Furberg, J. Connett, R. Prineas, 1986, The American journal of cardiology.

GOLD COPD stage I is not associated with increased risk of death.

C. Furberg, P. Quanjer, 2012, Respiratory medicine.

Outpatient management of severe COPD.

C. Furberg, Sonal Singh, Y. Loke, 2010, The New England journal of medicine.

Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.

T. J. Moore, C. Furberg, T. Moore, 2014, JAMA internal medicine.

Mortalityassociatedwithtiotropiummistinhalerinpatients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

P. Enright, C. Furberg, Sonal Singh, 2011 .

Cardiovascular disease risk prediction factors.

C. Furberg, A. Sniderman, 2012, Journal of the American Medical Association (JAMA).

Pharmaceutical policies: effects on rational drug use

C. Furberg, S. Hill, A. Oxman, 2006, Cochrane Database of Systematic Reviews.

AHA Conference Report on Cholesterol. Intervention studies.

D. Gordon, C. Furberg, E. Passamani, 1989, Circulation.

In reply

B. Psaty, C. Furberg, W. Longstreth, 1998 .

Drug treatment trials in hypertension: a review.

J. Cutler, C. Furberg, 1985, Preventive medicine.

assigned to them ? How should one analyse and interpret clinical trials in which patients don ' t take the treatments

C. Furberg, 2010 .

Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.

P. Wolf, R. Sacco, C. Furberg, 2001, Circulation.

Tiotropium for chronic obstructive pulmonary disease.

C. Furberg, Sonal Singh, Y. Loke, 2009, Drug and therapeutics bulletin.

Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.

P A Wolf, P. Wolf, R. Sacco, 2001, Circulation.

Studies on an extra pre-beta lipoprotein fraction.

C. Furberg, G. Dahlén, K. Svärdsudd, 1972, Acta medica Scandinavica. Supplementum.

Thoughts and Acts of Aggression/Violence Toward Others Reported in Association with Varenicline

T. J. Moore, C. Furberg, Joseph Glenmullen, 2010, The Annals of pharmacotherapy.

Should calcium antagonists be first-line agents in the treatment of cardiovascular disease? The public health perspective

B. Psaty, C. Furberg, 1996, Cardiovascular Drugs and Therapy.

Calcium antagonists: not appropriate as first line antihypertensive agents.

B. Psaty, C. Furberg, 1996, American journal of hypertension.

Pre-Beta1-Lipoprotein: Relationship to Angiographically Proven Coronary Heart Disease and to Lp(a) Lipoprotein

C. Furberg, G. Dahlén, K. Berg, 1974 .

The Beta-blocker Heart Attack Trial.

C. Furberg, 1985, Zeitschrift fur Kardiologie.

Prospective pravastatin pooling project: Relative risk reduction by baseline HDL and TG concentrations

A. Keech, E. Braunwald, C. Furberg, 2000 .

The Association Between Lipid Levels and the Risks of Incident Myocardial Infarction, Stroke, and Total Mortality: The Cardiovascular Health Study

T. Lumley, R. Kronmal, L. Fried, 2004, Journal of the American Geriatrics Society.

The safety risks of innovation: the FDA's Expedited Drug Development Pathway.

T. J. Moore, C. Furberg, T. Moore, 2012, JAMA.

Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study.

J. Gardin, L. Kuller, B. Psaty, 1994, American journal of epidemiology.

Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events

Michael E. Miller, C. Furberg, B. Pitt, 2000, Circulation.

Use of Diuretics in Treatment of Hypertension in the Elderly

L. Kuller, C. Furberg, H. Perry, 2012, Drugs.

Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.

S B Hulley, C. Furberg, W. Applegate, 1998, Controlled clinical trials.

Systolic Hypertension in the Elderly Program, Pilot Study (SHEP-PS): morbidity and mortality experience.

L. Kuller, C. Furberg, R. Mcdonald, 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

The Role of Beta-Blockers in Cardioprotection

C. Furberg, 1981 .

Methods and Findings

R. Kronmal, L. Kuller, B. Psaty, 2022 .

Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.

David Madigan, Jerry Avorn, D. Madigan, 2012, American heart journal.

Effect of Beta-blocker Therapy

C. Furberg, R. L. Bell, 2005 .

Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studies.

J. Cutler, L. Kuller, C. Furberg, 1986, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Public health policies: no place for surrogates.

C. Furberg, 2012, American journal of hypertension.

Unsuccessfully Treated Hypertension: A Major Public Health Problem With a Potential Solution.

C. Furberg, J. Blumenfeld, J. Sealey, 2017, American journal of hypertension.

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

C. Furberg, Sonal Singh, Y. Loke, 2008, JAMA.

Psychological risk factors in coronary artery disease.

P. Costa, C. Furberg, J. Blumenthal, 1987, Circulation.

Calcium channel blockers and cardiovascular risk in diabetes

B. Psaty, C. Furberg, M. Pahor, 1998, The Lancet.

Comparison of Effects on Left Ventricular Filling Pressure of Intravenous Nesiritide and High-Dose Nitroglycerin in Patients With Decompensated Heart Failure

J. Gardin, B. Gersh, J. Polak, 2004 .

The Costs of Antihypertensive Therapy-Reply

P. Whelton, J. Cutler, B. Psaty, 1996 .

Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials.

C. Furberg, J. Rushing, K. Pearce, 1995, Archives of family medicine.

Synergistic effects of a new beta-adrenergic blocker (pindolol) and isosorbidedinitrate during exercise in patients with coronary insufficiency

C. Furberg, L. Adolfsson, N. Areskog, 1972, European Journal of Clinical Pharmacology.

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

S Hulley, E. Vittinghoff, C. Furberg, 1998, JAMA.

Hormone therapy: time for replacement?

C. Furberg, D. Herrington, 1999, European Heart Journal.

Scientific Statement From the American Heart Association Use of Nonsteroidal Antiinflammatory Drugs : An Update for Clinicians: A

E. Antman, C. Furberg, A. Daugherty, 2007 .

Why guideline-making requires reform.

C. Furberg, A. Sniderman, 2009, JAMA.

Preventive cardiology academic award

C. Furberg, 1986 .

What CHF Trials have Shown to Date and What is Needed

C. Furberg, 1987 .

Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study.

B. Kestenbaum, C. Robinson-Cohen, I. D. de Boer, 2011, The Journal of clinical endocrinology and metabolism.

Major electrocardiographic abnormalities in persons aged 65 years and older (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group.

B. Psaty, N. Borhani, C. Furberg, 1992, The American journal of cardiology.

Drug safety: the different perspectives.

C. Furberg, 1998, Evidence-based cardiovascular medicine.

The unnecessary controversy.

B. Psaty, C. Furberg, M. Pahor, 1996, European heart journal.

Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.

E. Antman, C. Furberg, A. Daugherty, 2007, Circulation.

Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study

E. Vittinghoff, C. Furberg, D. Hunninghake, 2000, Annals of Internal Medicine.

Statin use and breast cancer: prospective results from the Women's Health Initiative.

A. LaCroix, J. Cauley, C. Furberg, 2006, Journal of the National Cancer Institute.

Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old

J. Guralnik, C. Furberg, M. Pahor, 1996, The Lancet.

Data Monitoring in Clinical Trials: A Case Studies Approach

Curt D. Furberg, David L. DeMets, Lawrence M. Friedman, 2005 .

How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?

B. Davis, J. Cutler, W. Cushman, 2013, Statistics in Medicine.

HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.

C. Furberg, J. Crouse, R. Byington, 1998, Atherosclerosis.

Cost-minimization and the number needed to treat in uncomplicated hypertension.

B. Psaty, C. Furberg, K. Pearce, 1998, American journal of hypertension.

Reductase inhibitor monotherapy and stroke prevention.

C. Furberg, J. Crouse, R. Byington, 1997, Archives of internal medicine.

Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Michael A. Proschan, Barry R. Davis, Curt D. Furberg, 1996 .

Hypertension and outcomes research. From clinical trials to clinical epidemiology.

B. Psaty, D. Siscovick, C. Furberg, 1995, American journal of hypertension.

Quality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine.

A E Fletcher, C. Bulpitt, C. Furberg, 1992, Hypertension.

Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.

C. Furberg, S. Yusuf, P. Held, 1989, BMJ.

Controlled Clinical Trials of Drug Treatment for Hypertension A Review

J. Cutler, C. Furberg, Stephen W. MacMahen, 1989, Hypertension.

The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials.

J. Cutler, C. Furberg, S. MacMahon, 1986, Progress in cardiovascular diseases.

Basic Study Design

David M. Reboussin, Lawrence M. Friedman, Curt D. Furberg, 2015 .

Clinical trial Data and Safety Monitoring Boards. The search for a constitution.

P. Armstrong, C. Furberg, 1995, Circulation.

Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study.

C. Furberg, M. Hlatky, T. Wenger, 1991, Journal of the American College of Cardiology.

Biologic determinants of propranolol disposition: Results from 1308 patients in the beta‐blocker heart attack trial *

P. Vokonas, C. Furberg, R. Byington, 1985, Clinical pharmacology and therapeutics.

Cholesterol reduction yields clinical benefit: impact of statin trials.

N. Santanello, J. Heyse, C. Furberg, 1998, Circulation.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

C. Furberg, J. de Graaf, K. Williams, 2011, Circulation. Cardiovascular quality and outcomes.

Effect of pravastatin in people with diabetes and chronic kidney disease.

M. Pfeffer, A. Keech, C. Furberg, 2005, Journal of the American Society of Nephrology : JASN.

Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).

C. Furberg, M. McGovern, M. Terrin, 2005, The American journal of cardiology.

Cholesterol reduction yields clinical benefit. A new look at old data.

N. Santanello, J. Heyse, C. Furberg, 1995, Circulation.

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Barry R. Davis, Curt D. Furberg, Henry R. Black, 2002, JAMA.

Depressive Symptoms and Risks of Coronary Heart Disease and Mortality in Elderly Americans

C. Tangen, C. Furberg, A. Dobs, 2000 .

Methods and Findings

R. Kronmal, L. Kuller, B. Psaty, 2022 .

A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers

Ian Harvey, Douglas G Altman, Andrew D Oxman, 2009, Canadian Medical Association Journal.

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.

J. Williamson, B. Psaty, C. Furberg, 2000, Diabetes care.

Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)

R. Coifman, B. Davis, H. Krumholz, 2017, Hypertension.

Ensuring the integrity of clinical practice guidelines: a tool for protecting patients

John P A Ioannidis, Jeanne Lenzer, J. Ioannidis, 2013, BMJ : British Medical Journal.

Prescription Drugs Associated with Reports of Violence Towards Others

C. Furberg, Joseph Glenmullen, T. Moore, 2010, PloS one.

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

B. Psaty, C. Furberg, W. Ray, 2004, JAMA.

Adrenergic beta-blockade and electrocardiographical ST-T changes.

C. Furberg, Curt Furberg, 2009, Acta medica Scandinavica.

Comparison of mortality risk for electrocardiographic abnormalities in men and women with and without coronary heart disease (from the Cardiovascular Health Study).

P. Chaves, B. Psaty, C. Furberg, 2006, The American journal of cardiology.

Adrenergic beta-receptor blockade and ECG changes of organic origin.

C. Furberg, F. Bergman, 1967, Scandinavian journal of clinical and laboratory investigation.

Adrenergic beta-receptor blockade in neurocirculatory asthenia

C. Furberg, C. Morsing, 1969, Pharmacologia Clinica.

Optimal risk factor management in the patient after coronary revascularization. A statement for healthcare professionals from an American Heart Association Writing Group.

V. Fuster, C. Furberg, M. Criqui, 1994, Circulation.

Propranolol-induced lipid changes and their prognostic significance after a myocardial infarction: the Beta-Blocker Heart Attack Trial experience.

C. Furberg, T. Craven, R. Byington, 1990, The American journal of cardiology.

Effects of single doses of alprenolol and two cardioselective β-blockers (H 87/07 and H 93/26) on exercise-induced angina pectoris

C. Furberg, G. Johnsson, L. Adolfsson, 2004, European Journal of Clinical Pharmacology.

Deepak L. Bhatt, E. Antman, C. Furberg, 2008, Circulation.

Ginkgo biloba for prevention of dementia: a randomized controlled trial.

Lewis H Kuller, Oscar L Lopez, Linda P Fried, 2008, JAMA.

Comparison of the design differences between the Ginkgo Evaluation of Memory study and the Guidage study

S. DeKosky, C. Furberg, R. Nahin, 2008, The journal of nutrition, health & aging.

The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia.

John Robbins, Lewis H Kuller, Oscar L Lopez, 2006, Contemporary clinical trials.

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

Ian Harvey, Douglas G Altman, Andrew D Oxman, 2009, Journal of clinical epidemiology.

Statistical Methods Used in Interim Monitoring

David M. Reboussin, Lawrence M. Friedman, Curt D. Furberg, 2015 .

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

Curt D. Furberg, Are H. Aastveit, C. Furberg, 2004, Clinical chemistry and laboratory medicine.

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.

B R Davis, B. Davis, P. Whelton, 1996, American journal of hypertension.

Nimodipine neuroprotection in cardiac valve replacement: report of an early terminated trial.

B. Troost, C. Furberg, J. Hammon, 1996, Stroke.

Risk Factors for Hospitalized Gastrointestinal Bleeding Among Older Persons

J. Polak, B. Psaty, C. Furberg, 2001, Journal of the American Geriatrics Society.

Incidence of and risk factors for atrial fibrillation in older adults.

L H Kuller, P M Rautaharju, R A Kronmal, 1997, Circulation.

Temporal trends in the use of anticoagulants among older adults with atrial fibrillation.

B. Psaty, C. Furberg, T. Manolio, 1999, Archives of internal medicine.

Effects of hyperventilation on ECG in patients with circulatory disturbances.

C. Furberg, H. Linderholm, 2009, Acta medica Scandinavica.

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials.

C. Furberg, S. Yusuf, K. Teo, 1993, JAMA.

B-Mode Ultrasound: A Noninvasive Method for Assessing Atherosclerosis

C. Furberg, W. Riley, M. Espeland, 2007 .

Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group.

R A Kronmal, R. Kronmal, J. Gardin, 1996, Stroke.

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and future risk of type 2 diabetes: results from the Cardiovascular Health Study.

J. Hokanson, C. Furberg, M. Cushman, 2012, The Journal of clinical endocrinology and metabolism.

Alcohol consumption and risk and prognosis of atrial fibrillation among older adults: the Cardiovascular Health Study.

L. Kuller, B. Psaty, D. Siscovick, 2007, American heart journal.

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II).

C. Furberg, M. Bond, M. Espeland, 1995, The American journal of cardiology.

Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction.

C. Furberg, R. Byington, J. Kostis, 1987, Journal of the American College of Cardiology.

Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project

A. Keech, E. Braunwald, C. Furberg, 2000, Circulation.

JNC 8: shortcomings in process and treatment recommendations.

C. Furberg, M. Alderman, 2014, American journal of hypertension.

Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.

Barry R Davis, B. Davis, P. Whelton, 2010, Archives of internal medicine.

Hypertension guidelines: criteria that might make them more clinically useful.

J. Laragh, B. Psaty, C. Furberg, 2002, American journal of hypertension.

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.

B. Davis, E. Braunwald, C. Furberg, 2002, European heart journal.

Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals.

L. Kuller, C. Furberg, M. Shlipak, 2004, Journal of the American Society of Nephrology : JASN.

Suicidal Behavior and Depression in Smoking Cessation Treatments

Curt D. Furberg, Thomas J. Moore, C. Furberg, 2011, PloS one.

Secondary prevention after myocardial infarction: a review of short-term acute phase trials.

C. Furberg, K. Eberlein, G. S. May, 1983, Progress in cardiovascular diseases.

Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone.

C. Furberg, H. Perry, W. M. Smith, 1985, The American journal of cardiology.

Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS).

T. Lumley, T. Rea, L. Kuller, 2005, American heart journal.

Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group.

R. Kronmal, J. Gardin, D. Siscovick, 1996, Hypertension.

C. Furberg, W. Ettinger, J. Wofford, 1992, Archives of internal medicine.

Long-Term and Short-Term Changes in Antihypertensive Prescribing by Office-Based Physicians in the United States

C. Furberg, R. Stafford, Jun Ma, 2006, Hypertension.

The necessity for clinical reasoning in the era of evidence-based medicine.

C. Furberg, K. Lachapelle, A. Sniderman, 2013, Mayo Clinic proceedings.

Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease.

C. Furberg, J. Hay, B. Pitt, 1996, The American journal of cardiology.

Experience collecting interim data on mortality: an example from the RALES study

S. Pocock, C. Furberg, J. Palensky, 2001, Current controlled trials in cardiovascular medicine.

Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.

C. Furberg, B. Pitt, R. Byington, 1995, The American journal of cardiology.

Issues in Data Analysis

Curt D. Furberg, David L. DeMets, Lawrence M. Friedman, 2010 .

Antihypertensive drugs decrease risk of Alzheimer disease

Qian-Li Xue, Sevil Yasar, Linda P Fried, 2013, Neurology.

Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study.

D. Gordon, B. Psaty, C. Furberg, 1998, Archives of internal medicine.

Clinical value of intracoronary streptokinase.

C. Furberg, 1984, The American journal of cardiology.

The use of β-adrenergic blocking drugs in patients with myocardial infarction

C. Furberg, W. Friedewald, W. Frishman, 1984 .

Effects of calcium channel blockers on survival after myocardial infarction

C. Furberg, S. Yusuf, 1987, Cardiovascular Drugs and Therapy.

Role of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

B. Davis, J. Cutler, M. Proschan, 2006, Circulation.

Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy

C. Furberg, W. Applegate, W. Riley, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Associations of Postmenopausal Estrogen Use With Cardiovascular Disease and Its Risk Factors in Older Women

B. Psaty, C. Furberg, T. Manolio, 1993, Circulation.

Risk Factors and Secondary Prevention in Women with Heart Disease: The Heart and Estrogen/progestin Replacement Study

E. Vittinghoff, C. Furberg, E. Barrett-Connor, 2003, Annals of Internal Medicine.

Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy.

A. LaCroix, B. Psaty, C. Furberg, 2001, Archives of internal medicine.

Task Force 2 : Psychological risk factors in coronary artery disease

P. Costa, C. Furberg, J. Blumenthal, 2005 .

Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study.

T. Lumley, N. Powe, B. Psaty, 2002, Archives of internal medicine.

Assessment of Health-Related Quality of Life

D. DeMets, D. Reboussin, C. Granger, 2010 .

Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

L. Goldman, B. Davis, J. Cutler, 2008, Journal of General Internal Medicine.

Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators.

C. Furberg, B. Pitt, R. Byington, 2000, Archives of internal medicine.

Conference Report From the American Diabetes Association and the Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus

C. Furberg, V. Howard, R. Goldberg, 2008 .

Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).

C. Furberg, M. McGovern, P. Canner, 2006, The American journal of cardiology.

Data monitoring in clinical trials

D. DeMets, C. Furberg, L. Friedman, 2006 .

Eligibility for Cholesterol Referral in Community-dwelling Older Adults

J. Gardin, L. Fried, L. Kuller, 1992, Annals of Internal Medicine.

Assessing and Reporting Adverse Events

D. DeMets, C. Furberg, L. Friedman, 2010 .

Can Atherosclerotic Progression and Its Complications Be Prevented After Revascularization ? Overview of the Pathogenesis of Bypass Graft Closure and Post-PTCA Restenosis Saphenous Vein Bypass Graft Disease

V. Fuster, C. Furberg, M. Criqui, 2005 .

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

E. Antman, S. Kaul, C. Furberg, 2008, The American Journal of Gastroenterology.

Organizing multicenter trials: lessons from cardiovascular prevention trials.

C. Furberg, 1991, Preventive medicine.

The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.

Ralph Lazzara, Peter J. Schwartz, Curt D. Furberg, 1994, Circulation.

Estrogen Replacement Therapy and MRI‐Demonstrated Cerebral Infarcts, White Matter Changes, and Brain Atrophy in Older Women: The Cardiovascular Health Study

M. Kraut, C. Furberg, T. Manolio, 2000, Journal of the American Geriatrics Society.

Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study

C. Lewis, N. Geller, C. Furberg, 2012, Clinical trials.

Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction.

B. Psaty, C. Furberg, S. Heckbert, 2002, Journal of clinical epidemiology.

Time to act on drug safety.

B. Psaty, C. Furberg, T. Moore, 1998, JAMA.

Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials

R. Brook, C. Furberg, P. Lawler, 2014, Journal of the American Heart Association.

Differences in Medical Care and Disease Outcomes Among Black and White Women With Heart Disease

Mark A Hlatky, C. Furberg, A. Jha, 2003, Circulation.

Classification Accuracy of Electrocardiographic Criteria for Left Ventricular Hypertrophy in Normal Weight and Overweight Older Adults

J. Gardin, D. Siscovick, N. Borhani, 1996 .

Risk of Hospitalized Gastrointestinal Bleeding in Persons Randomized to Diuretic, ACE‐Inhibitor, or Calcium‐Channel Blocker in ALLHAT

B. Davis, J. Williamson, S. Oparil, 2013, Journal of clinical hypertension.

Calcium channel blocker use and gastrointestinal tract bleeding among older adults.

B. Psaty, C. Furberg, T. Koepsell, 2002, Age and Ageing.

Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Results by Sex

B. Davis, P. Whelton, S. Oparil, 2013, Hypertension.

Treatment to Prevent Heart Attack Trial : Results by Sex Mortality and Morbidity During and After Antihypertensive and Lipid-Lowering

B. Davis, P. Whelton, W. Cushman, 2013 .

Treatment of Isolated Systolic Hypertension Is Most Effective in Older Patients With High-Risk Profile

L. Ferrucci, J. Williamson, J. Guralnik, 2001, Circulation.

Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study

J. Gardin, B. Gersh, J. Polak, 2002, Annals of Internal Medicine.

Relationship of Antihypertensive Treatment Regimens and Change in Blood Pressure to Risk for Heart Failure in Hypertensive Patients Randomly Assigned to Doxazosin or Chlorthalidone: Further Analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial

B. Davis, J. Cutler, C. Furberg, 2002, Annals of Internal Medicine.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Reporting and Interpreting of Results

D. DeMets, D. Reboussin, C. Granger, 2010 .

What is the Question

D. DeMets, D. Reboussin, C. Granger, 1996 .

Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience.

J. Cutler, C. Furberg, R. Prineas, 1986, Journal of the American College of Cardiology.

R. Klein, B. Klein, L. Kuller, 2003, Ophthalmology.

Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels.

J. Laragh, C. Furberg, M. Alderman, 2013, American journal of hypertension.

Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria

P. Savage, J. Polak, L. Kuller, 1999, The Lancet.

Current Controlled Trials in Cardiovascular Medicine: a new journal for a new age (http://cvm.controlled-trials.com)

C. Furberg, B. Pitt, 2000, Current controlled trials in cardiovascular medicine.

Time trends in the use of anti‐hypertensive medications: results from the Multi‐Ethnic Study of Atherosclerosis

B. Psaty, C. Furberg, R. Cooper, 2009, Pharmacoepidemiology and drug safety.

Prevalence, Prognosis, and Implications of Isolated Minor Nonspecific ST-Segment and T-Wave Abnormalities in Older Adults: Cardiovascular Health Study

B. Psaty, C. Furberg, J. Robbins, 2008, Circulation.

Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications

P. Enright, C. Furberg, Sonal Singh, 2012, Thorax.

Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

P. Enright, C. Furberg, Sonal Singh, 2011, BMJ : British Medical Journal.

Task Force 1: Sudden cardiac death

E. Eaker, C. Furberg, J. Dimsdale, 2005 .

Lipoprotein‐associated phospholipase A2 and risk of venous thrombosis in older adults

A. Folsom, B. Psaty, C. Furberg, 2008, American journal of hematology.

Consensus Documents American College of Cardiology Foundation Task Force on Clinical Expert Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the

E. Antman, C. Furberg, K. Mahaffey, 2008 .

The record on rosiglitazone and the risk of myocardial infarction.

Bruce M Psaty, B. Psaty, C. Furberg, 2007, The New England journal of medicine.

Lessons from overviews of cardiovascular trials.

C. Furberg, T. Morgan, 1987, Statistics in medicine.

Implications for Research

J. Cutler, C. Furberg, 1989 .

Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials

J. Williamson, B. Psaty, C. Furberg, 2000, The Lancet.

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

C. Furberg, Sonal Singh, Y. Loke, 2009, Canadian Medical Association Journal.

Cardiovascular disease risk status in elderly persons with renal insufficiency.

B. Psaty, C. Furberg, T. Manolio, 2002, Kidney international.

Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease.

C. Furberg, N. Wenger, M. Shlipak, 2001, Journal of the American College of Cardiology.

Traditional risk factors and subclinical disease measures as predictors of first myocardial infarction in older adults: the Cardiovascular Health Study.

J. Polak, L. Kuller, B. Psaty, 1999, Archives of internal medicine.

Health Outcomes Associated with Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis

B. Psaty, D. Siscovick, C. Furberg, 1998 .

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering.

C. Furberg, Ahsan Alam, K. Williams, 2012, Journal of clinical lipidology.

Characteristics and Baseline Clinical Predictors of Future Fatal Versus Nonfatal Coronary Heart Disease Events in Older Adults: The Cardiovascular Health Study

N. Powe, L. Kuller, B. Psaty, 2006, Circulation.

Hypertension, heart rate, use of antihypertensives, and incident prostate cancer.

R. Kronmal, C. Furberg, J. Weissfeld, 2001, Annals of epidemiology.

Association of Accelerometry‐Measured Physical Activity and Cardiovascular Events in Mobility‐Limited Older Adults: The LIFE (Lifestyle Interventions and Independence for Elders) Study

Mark A. Newman, Abbie P. Wrights, S. Studenski, 2017, Journal of the American Heart Association.

Venous thromboembolic events associated with hormone replacement therapy.

C. Furberg, S. Hulley, D. Grady, 1997, JAMA.

Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study

J. Hokanson, B. Psaty, C. Furberg, 2011, Diabetologia.

Lipoprotein-Associated Phospholipase A2 and Risk of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study

B. Psaty, C. Furberg, M. Cushman, 2009, Circulation. Heart failure.

Usefulness of T-axis deviation as an independent risk indicator for incident cardiac events in older men and women free from coronary heart disease (the Cardiovascular Health Study).

R. Kronmal, L. Fried, C. Furberg, 2001, The American journal of cardiology.

Behavioral consequences of hypertension and antihypertensive therapy.

R. E. Miller, C. Furberg, B. Pitt, 1987, Circulation.

Thiazolidinediones and Heart Failure

C. Furberg, Sonal Singh, Y. Loke, 2007, Diabetes Care.

Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods.

K. Bailey, C. Furberg, J. Wittes, 1986, Circulation.

Long-term Risk of Cardiovascular Events With Rosiglitazone

C. Furberg, Sonal Singh, Y. Loke, 2016 .

Weight Loss, Muscle Strength, and Angiotensin‐Converting Enzyme Inhibitors in Older Adults with Congestive Heart Failure or Hypertension

T. Lumley, B. Psaty, C. Furberg, 2005, Journal of the American Geriatrics Society.

Is the Guideline Process Replicable and, if Not, What Does This Mean?

C. Furberg, A. Sniderman, G. Thanassoulis, 2015, Progress in cardiovascular diseases.

The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease.

C. Furberg, K. Williams, A. Sniderman, 2014, Journal of clinical lipidology.

Long term propranolol treatment and changes in body weight after myocardial infarction.

C. Furberg, S. Rössner, R. Byington, 1990, BMJ.

Rosiglitazone and cardiovascular risk.

B. Psaty, C. Furberg, B. Psaty, 2007, The New England journal of medicine.

Use of calcium channel blockers and breast carcinoma risk in postmenopausal women

R. Kronmal, C. Furberg, J. Weissfeld, 1997, Cancer.

Are drugs within a class interchangeable?

David M Herrington, Bruce M Psaty, B. Psaty, 1999, The Lancet.

Effects of repeated work tests and adrenergic beta-blockade on electrocardiographic ST and T changes.

C. Furberg, 2009, Acta medica Scandinavica.

The effect of modified limb electrode positions on electrocardiographic wave amplitudes.

P M Rautaharju, R J Prineas, R S Crow, 1980, Journal of electrocardiology.

Reproducibility of Noninvasive Ultrasonic Measurement of Carotid Atherosclerosis: The Asymptomatic Carotid Artery Plaque Study

R W Barnes, C. Furberg, W. Applegate, 1992, Stroke.

Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.

C. Furberg, M. Bond, M. Espeland, 1992, Controlled clinical trials.

Progression and regression of carotid atherosclerosis in clinical trials.

C. Furberg, M. Bond, J. Crouse, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

When is equal not equal?

C. Furberg, K. Williams, A. Sniderman, 2010, Journal of clinical lipidology.

Achilles reflex time and sympathetic tone.

I. Ringqvist, C. Furberg, 1973, Upsala journal of medical sciences.

Secondary Prevention Trials After Myocardial Infarction

C. Furberg, 1988, Journal of cardiovascular pharmacology.

Five years of Trials

J. Grimshaw, C. Furberg, P. Rothwell, 2011, Trials.

Lead editorial: Trials – using the opportunities of electronic publishing to improve the reporting of randomised trials

J. Grimshaw, C. Furberg, P. Rothwell, 2006, Trials.

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

B. Davis, C. Furberg, J. Wright, 2001, Controlled clinical trials.

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.

B. Psaty, C. Furberg, M. Cushman, 2010, Atherosclerosis.

Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines.

C. Furberg, A. Sniderman, 2012, Journal of clinical epidemiology.

Age as a modifiable risk factor for cardiovascular disease

C. Furberg, A. Sniderman, 2008, The Lancet.

Report of the independent panel considering the retraction of two articles in The BMJ

H. Krumholz, C. Mulrow, C. Furberg, 2014, BMJ : British Medical Journal.

Consensus Reports

Lee C. Rogers, William H. Herman, Kirkman, 2011, Diabetes Care.

Treatment of hypertension: a failing report card.

C. Furberg, 2009, American journal of hypertension.

Clinical Implications of Recent Findings from the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT) and Other Studies of Hypertension

B. Psaty, C. Furberg, M. Pahor, 2001, Annals of Internal Medicine.

Comparisons in a competitive world: when is one drug superior to another?

C. Furberg, M. Weber, Michael A. Weber, 2000, American journal of hypertension.

National guidelines, clinical trials, and quality of evidence.

L. Kuller, B. Psaty, C. Furberg, 2000, Archives of internal medicine.

Impact of Clinical Trial Results on National Trends in α-Blocker Prescribing, 1996-2002

Stan N. Finkelstein, Curt D. Furberg, Iain M. Cockburn, 2004 .

mellitus undergoing coronary artery bypass grafting improve neurologic or neurobehavioral outcomes in patients without diabetes Attempted control of hyperglycemia during cardiopulmonary bypass fails to

B. Troost, C. Furberg, L. Wagenknecht, 2013 .

Attempted control of hyperglycemia during cardiopulmonary bypass fails to improve neurologic or neurobehavioral outcomes in patients without diabetes mellitus undergoing coronary artery bypass grafting.

B. Troost, C. Furberg, J. Hammon, 2005, The Journal of thoracic and cardiovascular surgery.

Isoprostane 8‐epi‐PGF2α is frequently increased in patients with muscle pain and/or CK‐elevation after HMG‐Co‐enzyme‐A‐reductase inhibitor therapy

H Sinzinger, C. Furberg, H. Sinzinger, 2001, Journal of clinical pharmacy and therapeutics.

Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated

M. Pencina, C. Furberg, J. Wilkins, 2018, Journal of the American Heart Association.

Spatial Distribution of Carotid Intimal‐Medial Thickness as Measured by B‐Mode Ultrasonography

C. Furberg, W. Riley, M. Espeland, 1994, Stroke.

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes

C. Furberg, Sonal Singh, 2008, Heart.

Taking a longer term view of cardiovascular risk: the causal exposure paradigm

Michael J Pencina, M. Pencina, C. Furberg, 2014, BMJ : British Medical Journal.

Recruitment of the elderly into a pharmacologic prevention trial: the Ginkgo Evaluation of Memory Study experience.

J. Williamson, L. Fried, S. DeKosky, 2006, Contemporary clinical trials.

Approaches to data analyses of clinical trials.

Curt D. Furberg, Lawrence M. Friedman, C. Furberg, 2012, Progress in cardiovascular diseases.

Stopping the Randomized Aldactone Evaluation Study Early for Efficacy

S. Pocock, C. Furberg, J. Wittes, 2006 .

Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.

L H Kuller, P. Wolf, J. Cutler, 1989, Stroke.

Antihypertensive drug therapies and the risk of ischemic stroke.

B M Psaty, N L Smith, B. Psaty, 2001, Archives of internal medicine.

Effect of aptin, a beta-adrenergic blocking agent, in arterial hypertension.

C. Furberg, G. Michaelson, 1969, Acta medica Scandinavica.

From knowledge to practice in chronic cardiovascular disease: a long and winding road.

C. Furberg, F. McAlister, S. Majumdar, 2004, Journal of the American College of Cardiology.

The FDA and drug safety: a proposal for sweeping changes.

Peter A Gross, C. Furberg, B. Strom, 2006, Archives of internal medicine.

Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort.

J. Gardin, C. Furberg, T. Manolio, 1999, The American journal of medicine.

Challenges to the funding of prevention research.

C. Furberg, 1994, Preventive medicine.

Ischemic episodes in 24-h ambulatory electrocardiograms of elderly persons: the Cardiovascular Health Study.

P M Rautaharju, J. Gardin, D. Siscovick, 1995, International journal of cardiology.

Separate and combined effects of pindolol and isosorbide dinitrate in standardized exercise tests of patients with angina pectoris.

I. Ringqvist, C. Furberg, S. Zetterquist, 1975, Current Therapeutic Research.

Pilot Study of the Systolic Hypertension in the Elderly Program Type of event ICD number Outline of criteria for event Hypertensive Stroke Left ventricular failure Transient ischemic attack Atherosclerotic Myocardial infarction Sudden death Angina pectoris Coronary artery surgery

P. Wolf, J. Cutler, L. Kuller, 2005 .

Beyond hypertension: Toward guidelines for cardiovascular risk reduction

J. Laragh, B. Psaty, C. Furberg, 2004 .

Social Participation Modifies the Effect of a Structured Physical Activity Program on Major Mobility Disability Among Older Adults: Results From the LIFE Study

Michael E. Miller, Mark A. Newman, Abbie P. Wrights, 2018, The journals of gerontology. Series B, Psychological sciences and social sciences.

Methodological issues facing studies of atherosclerotic change.

C. Furberg, W. Riley, M. Espeland, 1993, Circulation.

Diabetes and Cognitive Decline in Older Adults: The Ginkgo Evaluation of Memory Study

J. Williamson, R. Crum, S. DeKosky, 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.

Parecoxib, valdecoxib, and cardiovascular risk.

B. Psaty, C. Furberg, G. FitzGerald, 2005, Circulation.

A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization

Elsayed Z Soliman, C. Furberg, E. Soliman, 2011, Trials.

Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians.

Stacey L. Sheridan, C. Furberg, A. Viera, 2011, Preventive medicine.

Procedures of data and safety monitoring committees.

S. Pocock, C. Furberg, 2001, American heart journal.

The systolic hypertension in the elderly pilot program: methodological issues.

C. Furberg, D. Black, 1988, European heart journal.

Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.

C. Furberg, M. Espeland, R. Byington, 1995, The American journal of cardiology.

Risk of Congestive Heart Failure in an Elderly Population Treated with Peripheral Alpha‐1 Antagonists

L. Kuller, B. Psaty, C. Furberg, 2004, Journal of the American Geriatrics Society.

Distribution and Correlates of Lipoprotein‐Associated Phospholipase A2 in an Elderly Cohort: The Cardiovascular Health Study

B. Psaty, C. Furberg, M. Cushman, 2008, Journal of the American Geriatrics Society.

Understanding drug safety and how to maximize it for patients.

C. Furberg, 2011, JAAPA : official journal of the American Academy of Physician Assistants.

The Association Of Antihypertensive Agents with MRI White Matter Findings and with Modified Mini‐Mental State Examination in Older Adults

B. Psaty, C. Furberg, S. Heckbert, 1997, Journal of the American Geriatrics Society.

Does Ginkgo biloba Reduce the Risk of Cardiovascular Events?

L. Kuller, O. Lopez, S. DeKosky, 2010, Circulation. Cardiovascular quality and outcomes.

Turning over a new leaf

S. DeKosky, C. Furberg, 2008, Neurology.

Use of Herbal Medicine and Other Dietary Supplements in Community‐Dwelling Older People: Baseline Data from the Ginkgo Evaluation of Memory Study

S. DeKosky, C. Furberg, A. Fitzpatrick, 2006, Journal of the American Geriatrics Society.

Assessment and Reporting of Harm

D. DeMets, D. Reboussin, C. Granger, 2015 .

Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis

C. Furberg, Sonal Singh, Y. Loke, 2011, Thorax.

Questioning statin therapy for older patients

N. Jewell, C. Furberg, J. Abramson, 2020, The Lancet.

The effect of a ganglionic blocking agent (chlorisondamine) on electrocardiogram, physical working capacity and hemodynamics in patients with vasoregulatory asthenia.

C. Furberg, H. Linderholm, O. Arvedson, 2009, Acta medica Scandinavica. Supplementum.

Electronic Health Data for Postmarket Surveillance: A Vision Not Realized

C. Furberg, Curt D Furberg, Thomas J Moore, 2015, Drug Safety.

The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Perindopril pROtection aGainst REcurrent Stroke Study.

B. Psaty, C. Furberg, N. Weiss, 2002, American journal of hypertension.

27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 2. Clinical epidemiology: the conceptual basis for interpreting risk factors.

P. Whelton, B. Psaty, C. Furberg, 1996, Journal of the American College of Cardiology.

Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women.

J. Williamson, L. Kuller, O. Lopez, 2010, American journal of hypertension.

IEWPOINT rom Knowledge to Practice in Chronic ardiovascular Disease : A Long and Winding Road

C. Furberg, F. McAlister, U. Majumdar, 2016 .

Survival analysis of adverse effects data in the Beta‐Blocker Heart Attack Trial

B R Davis, B. Davis, C. Furberg, 1987, Clinical pharmacology and therapeutics.

Overview of completed sudden death trials: US experience.

C. Furberg, 1987, Cardiology.

Adrenergic beta-blockade and physical working capacity.

C. Furberg, 2009, Acta medica Scandinavica.

Propranolol and angina pectoris. An analysis of the different responses to the drug in patients with angina pectoris.

C. Furberg, K. Jacobsson, 2009, Acta medica Scandinavica.

Beta-adrenergic blockade and central circulation during exercise in sitting position in healthy subjects.

C. Furberg, G. von Schmalensee, 1968, Acta physiologica Scandinavica.

Potential problems with random zero sphygmomanometer

C. Furberg, T. Manolio, N. Borhani, 1990, The Lancet.

What are the weaknesses of randomized controlled clinical trials

C. Furberg, B. Furberg, 2007 .

Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study

B. Psaty, D. Siscovick, C. Furberg, 2010, BMJ : British Medical Journal.

The risk of myocardial infarction associated with antihypertensive drug therapies.

T. Raghunathan, B. Psaty, D. Siscovick, 1995, JAMA.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

R. Krauss, S. Humphries, C. Furberg, 2006, Journal of internal medicine.

The FDA and new safety warnings.

C. Furberg, Sonal Singh, T. Moore, 2012, Archives of internal medicine.

Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014

C. Furberg, Michael R. Cohen, D. Mattison, 2016, Pharmacoepidemiology and drug safety.

Expedited review of new drugs--reply.

C. Furberg, T. Moore, 2013, JAMA.

Clinical Trials in Hypertension—Reply

B. Psaty, C. Furberg, N. Weiss, 2006 .

Hypertension guidelines: Criteria that might make them more clinically useful

J. Laragh, B. Psaty, C. Furberg, 2002 .

Evidence-based medicine

B. Psaty, C. Furberg, C. Rhoads, 2000, Journal of General Internal Medicine.

British guidelines on managing hypertension

B. Psaty, C. Furberg, B. Psaty, 1999, BMJ.

Meta-analysis of Hypertension Trials in Diabetic Patients Response to Parving and Rossing

B. Psaty, C. Furberg, M. Pahor, 2001 .

Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study

E. Vittinghoff, C. Furberg, D. Hunninghake, 2000, Annals of Internal Medicine.

A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women.

David C. Atkins, R. Prentice, B. Psaty, 1993, Archives of internal medicine.

Carotid Doppler high-intensity transient signals in dilated cardiomyopathy.

C. Furberg, D. Kitzman, C. Tegeler, 2000, American heart journal.

Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment

A. Keech, C. Furberg, A. Wägner, 2003, The Lancet.

Niacin decreases myocardial infarction and total mortality in patients with metabolic syndrome: Results from the coronary drug project

C. Furberg, M. McGovern, M. Terrin, 2003 .

Correlates of QT prolongation in older adults (the Cardiovascular Health Study). Cardiovascular Health Study Collaborative Research Group.

N. Borhani, C. Furberg, P. Rautaharju, 1994, The American journal of cardiology.

Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study

C. Furberg, A. Fitzpatrick, W. Longstreth, 2001, Neurology.

How should one analyse and interpret clinical trials in which patients don't take the treatments assigned to them?

C. Furberg, Curt D Furberg, 2010, Journal of the Royal Society of Medicine.

Current Controlled Trials in Cardiovascular Medicine

M. Sevick, C. Furberg, C. Furberg, 2004 .

Pharmaceutical policies: effects on rational drug use

C. Furberg, S. Hill, A. Oxman, 2006 .

Turning over a new leaf: Ginkgo biloba in prevention of dementia?

S. DeKosky, C. Furberg, 2008 .

Coronary heart disease in the elderly: Review of current knowledge and research recommendations

C. Furberg, N. Wenger, E. Pitt, 1988, Clinical cardiology.

Task Force 4: Behavioral consequences of hypertension and antihypertensive therapy

C. Furberg, B. Pitt, S. Julius, 1987 .

FAMILIAL QT PROLONGATION and RISK OF SUDDEN DEATH

C. Furberg, H. Hörnell, 1975, Acta paediatrica Scandinavica.

The Harms of Antipsychotic Drugs: Evidence from Key Studies

C. Furberg, T. Moore, 2016, Drug Safety.

The Cardiovascular Health Study: design and rationale.

R. Kronmal, J. Gardin, L. Fried, 1991, Annals of epidemiology.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications

P. Enright, C. Furberg, Sonal Singh, 2012, Thorax.

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

C. Furberg, Sonal Singh, Y. Loke, 2008, JAMA.

The necessity for clinical reasoning in the era of evidence-based medicine.

C. Furberg, K. Lachapelle, A. Sniderman, 2013, Mayo Clinic proceedings.

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

C. Furberg, A. Oxman, D. Altman, 2009, Journal of clinical epidemiology.

Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.

C. Furberg, S. Yusuf, P. Held, 1989, BMJ.

Lead editorial: Trials – using the opportunities of electronic publishing to improve the reporting of randomised trials

J. Grimshaw, C. Furberg, P. Rothwell, 2006, Trials.

Overtreatment and undertreatment of hypertension

C. Furberg, G. Berglund, B. Psaty, 1994, Journal of internal medicine.

Cardiovascular disease risk prediction factors.

C. Furberg, A. Sniderman, 2012, JAMA.

Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering.

C. Furberg, Ahsan Alam, K. Williams, 2012, Journal of clinical lipidology.

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis

C. Furberg, Sonal Singh, Y. Loke, 2011, Canadian Medical Association Journal.

Title : Intravenous magnesium prevents atrial fibrillation after coronary artery bypass grafting : a meta-analysis of 7 double-blind , placebo-controlled , randomized clinical trials

J. Grimshaw, C. Furberg, D. Altman, 2012 .

Issues in Data Analysis

D. DeMets, C. Furberg, L. Friedman, 2010 .

Prevalence, Prognosis, and Implications of Isolated Minor Nonspecific ST-Segment and T-Wave Abnormalities in Older Adults: Cardiovascular Health Study

C. Furberg, J. Robbins, D. Lloyd‐Jones, 2008, Circulation.

Long-Term Follow-Up of Participants With Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

B. Davis, S. Oparil, W. Cushman, 2011, Circulation.

Response to Letter Regarding Article, “Physical Activity and Incidence of Atrial Fibrillation in Older Adults: The Cardiovascular Health Study”

D. Mozaffarian, D. Siscovick, C. Furberg, 2009 .

EFFECT OF APTIN, A β‐ADRENERGIC BLOCKING AGENT, IN ARTERIAL HYPERTENSION

C. Furberg, G. Michaelson, 2009 .

Controlling prescription drug expenditures: a report of success.

W. Ambrosius, C. Furberg, David P. Miller, 2007, The American journal of managed care.

Sudden cardiac death. Stress and cardiac arrhythmias.

E. Eaker, C. Furberg, J. Dimsdale, 1987, Circulation.

Blood Pressure and Cardiovascular Disease

C. Furberg, E. Soliman, B. Psaty, 2010 .

JNC VI: timing is everything

C. Furberg, B. Psaty, 1997, The Lancet.

Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk.

C. Furberg, P. Lawler, K. Williams, 2012, The American journal of cardiology.

Approaches to data analyses of clinical trials.

C. Furberg, L. Friedman, 2012, Progress in cardiovascular diseases.

Assessment of temporal bias in longitudinal measurements of carotid intimal-medial thickness in the Asymptomatic Carotid Artery Progression Study (ACAPS). ACAPS Research Group.

C. Furberg, W. Riley, T. Craven, 1996, Ultrasound in medicine & biology.

Lessons Learned from a Prospective Meta‐analysis

T M Morgan, C. Furberg, M. Sager, 1995, Journal of the American Geriatrics Society.